Akeso wins China NMPA Phase I clearance for EGFR/TROP2 bispecific ADC AK158D1

• China’s NMPA cleared a Phase I trial for Akeso’s EGFR/TROP2 bispecific ADC candidate AK158D1 in advanced solid tumors.
• The decision moves AK158D1 into clinical development, expanding the group’s clinical-stage ADC portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609170234PR_NEWS_USPR_____CN50489) on September 17, 2026, and is solely responsible for the information contained therein.